Merus Stock Soars 37% On Strong Interim Data For Cancer Drug

(RTTNews) - Merus N.V. (MRUS) surged 37.5 percent to $57.18 on Friday, gaining $15.58 after announcing yesterday encouraging interim results from its Phase II trial of Petosemtamab in combination with Merck's Keytruda for patients with recurrent or metastatic head and neck squamous cell carcinoma.

MRUS opened at $49.69 and ranged between $49.44 and $57.23 in today's session on the Nasdaq. Volume soared to 5.5 million shares, far exceeding its average daily volume of 836,000. The stock previously closed at $41.60.

Over the past 52 weeks, Merus shares have traded between $33.19 and $61.61. A Phase III trial comparing the Petosemtamab-Keytruda combination to Keytruda alone is currently underway.